These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors. Notas G; Kolios G; Mastrodimou N; Kampa M; Vasilaki A; Xidakis C; Castanas E; Thermos K; Kouroumalis E J Hepatol; 2004 May; 40(5):792-8. PubMed ID: 15094227 [TBL] [Abstract][Full Text] [Related]
7. The role of somatostatin analogs in the management of hepatocellular carcinoma. D'Agostino L; Manguso F; Pivonello R; Colao A J Endocrinol Invest; 2003; 26(8 Suppl):131-3. PubMed ID: 15233229 [No Abstract] [Full Text] [Related]
8. Antineoplastic mechanism of Octreotide action in human hepatoma. Chen X; Liu Z; Ai Z Chin Med J (Engl); 2001 Nov; 114(11):1167-70. PubMed ID: 11729512 [TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Cebon J; Findlay M; Hargreaves C; Stockler M; Thompson P; Boyer M; Roberts S; Poon A; Scott AM; Kalff V; Garas G; Dowling A; Crawford D; Ring J; Basser R; Strickland A; Macdonald G; Green M; Nowak A; Dickman B; Dhillon H; Gebski V; Br J Cancer; 2006 Oct; 95(7):853-61. PubMed ID: 16953241 [TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. Abdel-Rahman O; Lamarca A; Valle JW; Hubner RA Endocr Relat Cancer; 2014; 21(6):R485-93. PubMed ID: 25336571 [TBL] [Abstract][Full Text] [Related]
11. Octreotide in hepatocellular carcinoma. Shouval D Gut; 1998 Mar; 42(3):316-7. PubMed ID: 9577332 [No Abstract] [Full Text] [Related]
12. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Becker G; Allgaier HP; Olschewski M; Zähringer A; Blum HE; Hepatology; 2007 Jan; 45(1):9-15. PubMed ID: 17187405 [TBL] [Abstract][Full Text] [Related]
13. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Kouroumalis E; Skordilis P; Thermos K; Vasilaki A; Moschandrea J; Manousos ON Gut; 1998 Mar; 42(3):442-7. PubMed ID: 9577356 [TBL] [Abstract][Full Text] [Related]
14. Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatment. Rahmi G; Malka D; Tomasic G; Dromain C; Ducreux M; Boige V J Clin Oncol; 2007 Jun; 25(16):e15-6. PubMed ID: 17538153 [No Abstract] [Full Text] [Related]
16. Post-TACE combination therapy of heparin and octreotide results in decreased tumor metastasis in extrahepatic tumorigenesis. Jia W; Feng K; Fan P; Fan G; Yang S; Zhang T; Wei Q; Qian L Cell Biochem Biophys; 2012 Jan; 62(1):35-40. PubMed ID: 21822978 [TBL] [Abstract][Full Text] [Related]
17. The results of a randomized study on the use of long-acting octreotide in hepatocellular carcinoma. Borbath I; Horsmans Y Hepatology; 2003 Feb; 37(2):477-8; author reply 478. PubMed ID: 12575712 [No Abstract] [Full Text] [Related]
18. Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma. Hua YP; Yin XY; Peng BG; Li SQ; Lai JM; Liang HZ; Liang LJ Chemotherapy; 2009; 55(5):312-20. PubMed ID: 19590186 [TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience. Montella L; Addeo R; Caraglia M; Faiola V; Guarrasi R; Vincenzi B; Palmeri A; Capasso E; Nocera V; Tarantino L; Ariete M; Martorelli A; Del Prete S Oncol Rep; 2008 Aug; 20(2):385-90. PubMed ID: 18636202 [TBL] [Abstract][Full Text] [Related]
20. Megestrol treatment in patients with hepatocellular carcinoma. Farinati F; Gianni S; De Giorgio M; Fiorentini S Br J Cancer; 2001 Nov; 85(10):1606-8. PubMed ID: 11720452 [No Abstract] [Full Text] [Related] [Next] [New Search]